About

EuBiologics is listed biopharmaceutical company located in Korea, developing human vaccines against infectious disease using two proprietary technologies, EcML (Monophosphoryl Lipid A, TLR4 agonist) and recombinant CRM197 (Carrier protein). We have currently 7 vaccines in the pipeline. TCV (Typhoid Conjugate Vaccine, NDA), PCV (Pneumococcal Conjugate Vaccine, Ph I completed), MCV (Meningococcal Conjugate Vaccine, Ph I completed), HZV (Herpes Zoster Virus, Non-Clinical), RSV (Respiratory Syncytial Virus, Non-clinical), OCV (Oral Cholera Vaccine, commercialized) and EuCorVac-19 (COVID-19, Ph III). OCV have been supplied to UNICEF/PAHO and several more countries since 2016 after WHO-PQ and captured more than 90% of the public cholera vaccine market. EuBiologics can also offer advanced cGMP-level facilities providing fully integrated CRMO services for mammalian cell and microbial derived biopharmaceutical, from cell line development to large-scale commercial GMP production. EuBiologics is especially specialized in a variety of protein-based therapeutics and vaccines as we have had plenty of experience working with many innovative biotech in getting the right therapeutics. We possess extensive working knowledge of developing and manufacturing different types of vaccine. About EuBiologics Co., Ltd. EuBiologics is a publicly traded biopharmaceutical company specializing in human vaccines targeting infectious diseases. We leverage our proprietary adjuvant (TLR4 agonist, E. coli-derived) and recombinant carrier protein (CRM197), both of which have global IP protections, to develop novel vaccines. About EuBiologics Co., Ltd. EuBiologics is a publicly traded biopharmaceutical company specializing in human vaccines targeting infectious diseases. We leverage our proprietary adjuvant (TLR4 agonist, E. coli-derived) and recombinant carrier protein (CRM197), both of which have global IP protections, to develop novel vaccines. x